360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Generic Version

Type: Keyphrase

Name: Generic Version

First reported 8 hours ago - Updated 1 hour ago - 1 reports

Ranbaxy Laboratories Ltd

EU fines Ranbaxy, others for blocking cheaper drugs

ReutersBrussels: Nine drugmakers, including Denmark's Lundbeck and India's Ranbaxy, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.The punishments ... [Published msn.co.in - 8 hours ago]

Entities: Ranbaxy Laboratories Ltd, European Union, Drugs

First reported 2 hours ago - Updated 2 hours ago - 1 reports

Plans to ban pay-to-delay deals justified, says UK health economist

Pay-to-delay deals which hold up the release of generic drugs into the market can lead to consumers paying up to five times more for some medicines, a UK health economist has found.The news comes as the European Union's anti-trust regulator prepares to ... [Published Pharmaceutical Technology - 2 hours ago]

Entities: Adderall XR, OFT Office of Fair Trading, Drugs, ADHD

First reported 8 hours ago - Updated 3 hours ago - 4 reports

European Union

EU fines drugs firms 150 mn euros for delaying cheap generics (AFP)

BRUSSELS (AFP) - The EU executive on Wednesday imposed hefty fines of around 150 million euros on pharmaceutical firms including Denmark's Lundbeck for colluding to delay the sale a decade ago of a cheap generic version of a widely sold anti-depressa ... [Published Yahoo! News Australia - 3 hours ago]

Entities: Cheap, European Union, Drugs

First reported Jun 18 2013 - Updated 5 hours ago - 3 reports

Two rulings (part 2)

In a ruling handed down Monday, the U.S. Supreme Court assured federal regulators considerable leeway to prevent drug companies from striking deals at the expense of consumers.Drug manufacturers who hold lucrative patents on brand-name drugs can pay competitors ... [Published Akron Beacon Journal - 15 hours ago]

Entities: Drugs, Patent, Antitrust, AndroGel, courts

First reported 6 hours ago - Updated 5 hours ago - 1 reports

Pfizer Inc

Pfizer settles with patients

Drug maker Pfizer will pay $4.8 million in compensation to Canadians who tried to commit suicide after being prescribed a drug to treat seizures.The class-action settlement, announced Wednesday by law firm Siskinds, applies to patients who took Neurontin ... [Published Sault Star Online - 6 hours ago]

Entities: Pfizer Inc, Neurontin, Patient

First reported 8 hours ago - Updated 8 hours ago - 1 reports

E.U. Fines Drug Companies for Delaying Generics

Antitrust regulators levied a total of $195.5 million in penalties for what they said were companies’ attempts to block a less expensive generic version of a popular antidepressant. ... [Published New York Times - 8 hours ago]

Entities: Drugs, European Union, Generic Version

First reported 10 hours ago - Updated 9 hours ago - 1 reports

FDA Food & Drug Administration

Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate...

(MPI) continues to pursue the approval of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple dose vial; a generic version of Bristol-Myers Squibb’s drug formerly known as Delalutin™. While ... [Published PRWeb - 10 hours ago]

Entities: Abbreviated New Drug Application, FDA Food & Drug Administration, current Good Manufacturing Practices, Drugs

First reported Jun 18 2013 - Updated 17 hours ago - 1 reports

Supreme Court rules 'pay-for-delay' drug deals can be illegal

A divided U.S. Supreme Court ruled Monday that some "pay-for-delay" settlements between drug companies and their competitors violate antitrust laws. The 5-3 decision, a limited victory for the Obama administration, paves the way for federal regulators ... [Published Health Leaders - Jun 18 2013]

Entities: Drugs, Supreme Court, Illegal

First reported 19 hours ago - Updated 19 hours ago - 1 reports

Xubex Offers the Lowest Price on FDA-Approved Generic Lipitor®

- Jun. 18, 2013 - WINTER PARK, Fla. -- Xubex has been selling a generic version of Lipitor® since June 3, 2013, customers have been able to order Atorvastatin at an even greater discount to retail pharmacies without the need for any coupons, discount ... [Published Prlog - 19 hours ago]

Entities: Lipitor, Plavix, Trademark, Drugs, Generic Version

First reported Jun 17 2013 - Updated Jun 18 2013 - 9 reports

Drugmakers may face ‘pay for delay’ suits, high court rules

Drugmakers can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.The 5-3 ruling is largely a victory for the Federal Trade ... [Published Indianapolis Business Journal - Jun 18 2013]

Entities: Stephen Breyer, Anti-Competition, Patent, Antitrust

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Actavis files ANDA for generic version of Diprivan

Actavis, Inc., a specialty pharmaceutical company developing generic and over-the-counter pharmaceutical products, has filed an abbreviated new drug application or ANDA, with the FDA seeking approval to market Propofol injection 10mg/mL. Actavis' ANDA ... [Published Individual.com - Jun 18 2013]

Entities: Abbreviated New Drug Application, Actavis, Diprivan, Generic Version

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Does a Top Drugmaker’s Playbook Stifle Competition?

If you owned the bestselling prescription drug of all time and its patent was about to expire, how would you prepare for competition from generic drugs?You might look at what Pfizer did when time was running out on its patent for the cholesterol-lowering ... [Published AARP Bulletin Today - Jun 17 2013]

Entities: Lipitor, Generic Version, Pfizer Inc

Quotes

"My research shows that in this respect, the challenges by the FTC, attempts to introduce legislation in the US Congress to ban such deals, and the investigations by the OFT and EU Commission are justified" said Dr Bokhari

Plans to ban pay-to-delay deals justified, says UK health economist [Published Pharmaceutical Technology - 2 hours ago]

"Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints. The Commission will not tolerate such anticompetitive practices"

EU fines drugs firms 150 mn euros for delaying cheap generics (AFP) [Published West Australian - 3 hours ago]

...to stay out of its market and delay the entry of cheaper medicines," said Joaquin Almunia, the European Commission's competition commissioner. "We are confirming that the..."

Drug firms fined for blocking rivals [Published NewsRT.co.uk - 3 hours ago]

It is the first fine of this kind in Europe and analysts say it could set a precedent. "This is the first case of likely many for which we will see fine imposed" said Deutsche Bank analysts Tim Race

Drug firms fined for blocking rivals [Published BBC - 3 hours ago]

More Content

sort by: Date \| Relevance
Dr Reddy’s sued over patent infringement [Published Financial Chronicle - 29 mins ago]
Plans to ban pay-to-delay deals justified, says... [Published Pharmaceutical Technology - 2 hours ago]
Ranbaxy, 8 others fined for blocking cheaper dr... [Published Hindu Business Line - 3 hours ago]
EU fines drugs firms 150 mn euros for delaying ... [Published West Australian - 3 hours ago]
EU fines drugs firms 150 mn euros for delaying ... [Published Yahoo! News Australia - 3 hours ago]
Drug firms fined for blocking rivals [Published NewsRT.co.uk - 3 hours ago]
Drug firms fined for blocking rivals [Published BBC - 3 hours ago]
More Americans choosing generic drugs [Published Hesperian Beacon - 4 hours ago]
FTC Allowed to Stop Brand Drug Firms from Payin... [Published AllGov - 5 hours ago]
EU Fines Danish Pharma Company Lundbeck, Generi... [Published International Business Times UK - 5 hours ago]
Almunia fines Lundbeck and rivals for fudging c... [Published European Voice - 6 hours ago]
European regulator fines Ranbaxy and 8 others f... [Published domain-b - 6 hours ago]
Pfizer settles with patients [Published Sault Star Online - 6 hours ago]
Ranbaxy filed Rs 81 crore by EU for delaying ge... [Published NDTV Profit - 7 hours ago]
Actavis, Kissei File Lawsuits Over Rapaflo Patent [Published FinanzNachrichten.de - 7 hours ago]
EU fines Lundbeck and others 146 mln euros for ... [Published Sharenet - 7 hours ago]
EU fines Ranbaxy, others for blocking cheaper d... [Published msn.co.in - 8 hours ago]
E.U. Fines Drug Companies for Delaying Generics [Published New York Times - 8 hours ago]
Actavis And Kissei File Lawsuits Against Sandoz... [Published WMCTV.com - 8 hours ago]
Actavis (ACT), Kissei Pharma Sue Sandoz, Hetero... [Published Street Insider - 8 hours ago]
What's YOUR risk of impotence? As our new calcu... [Published Mail Online UK - 8 hours ago]
European Pharmaceuticals Fined $195 Million [Published VOA News - 8 hours ago]
Current Progress Towards ANDA Approval of Hydro... [Published BizWire Express - 9 hours ago]
Antitrust: Commission fines Lundbeck and other ... [Published European Commission - 9 hours ago]
Current Progress Towards ANDA Approval of Hydro... [Published Bio-Medicine - 9 hours ago]
Current Progress Towards ANDA Approval of Hydro... [Published BioPortfolio - 9 hours ago]
Current Progress Towards ANDA Approval of Hydro... [Published PRWeb - 10 hours ago]
UPDATE 1-EU fines Lundbeck, 8 others 146 mln eu... [Published CNBC - 10 hours ago]
InSite Vision to join Merck & Pfizer to file pa... [Published PharmaBiz - 12 hours ago]
Two rulings (part 2) [Published Akron Beacon Journal - 15 hours ago]

Blogs

sort by: Date \| Relevance
U.S. court finds Novo Nordisk Prandin diabetes ... [Published Yahoo! Health News - 23 hours ago] (Reuters) - A U.S. appeals court found the patent on Novo Nordisk's Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday. ... ...
Pfizer Sues to Block Generic AzaSite Sales and ... [Published Wall St. Cheat Sheet - Jun 17 2013] Pfizer ( NYSE:PFE ): Current price $29.05Merck & Co. ( NYSE:MRK ) and Pfizer have sued the generic drugmaker Mylan Pharmaceuticals in order to disallow it from selling a copy of AzaSite, which is an antibiotic eye solution for combating bacterial conjunctivitis. ...
Pfizer Sues to Block Generic AzaSite Sales and ... [Published Wall St. Cheat Sheet - Jun 17 2013] Pfizer ( NYSE:PFE ): Current price $29.05 Merck & Co. ( NYSE:MRK ) and Pfizer have sued the generic drugmaker Mylan Pharmaceuticals in order to disallow it from selling a copy of AzaSite, which is an antibiotic eye solution for combating bacterial ...
Supreme Court Decision Will Likely Reduce Presc... [Published Firedoglake - Jun 17 2013] Thanks to the Supreme Court, it may soon become slightly easier to get the cheaper generic version of some medications. In the case of FTC v. Actavis, Inc. the Court decided 5-3 that the FTC has the power to try to stop “pay for delay” on anti-trust ...
Supreme Court Rules FTC Can Challenge Deals Int... [Published The Consumerist - Jun 17 2013] ( Solo ) When a generic version of a drug comes on the market, the holder of the brand-name drug’s patent stands to see a steep drop in sales as many customers switch to the lower-price option. Thus, some companies will go to great lengths to delay ...

Press Releases

sort by: Date \| Relevance
InSite Vision Announces Joint Patent Infringeme... [Published Business Wire Health News - Jun 17 2013]
ACETO Subsidiary, Rising Pharmaceuticals, to La... [Published GlobeNewswire: Acquisitions News - Jun 11 2013]
ACETO Subsidiary, Rising Pharmaceuticals, Launc... [Published GlobeNewswire: Acquisitions News - Jun 04 2013]
Shire Settles Patent Infringement Lawsuit Again... [Published PR Newswire: General Business - May 31 2013]
Perrigo Confirms Patent Challenge For Generic V... [Published PR Newswire: Policy & Public Interest - May 29 2013]